Bard expanding presence in vascular graft market via Impra acquisition.
This article was originally published in The Gray Sheet
BARD TO EXPAND VASCULAR GRAFT PRESENCE VIA IMPRA ACQUISITION by gaining the number two player worldwide in the polytetrafluoroethylene (PTFE) vascular graft market. Bard announced Aug. 5 that it has entered an agreement to acquire Tempe, Arizona-based Impra in a cash transaction "targeted for completion in the third quarter." Terms of the deal were not disclosed.
You may also be interested in...
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.